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I In nt tr ro od du uc ct ti io on n
Though epicardial fat is avisceral thoracic fat accumulated
along the heart, it has not been studied thoroughly and rela-
tively neglected component of the heart.
1) Like other visceral
adipose tissue, it might function as an endocrine organ secret-
ing hormones and as an inflammatory tissue secreting cyto-
kines and chemokines. Moreover, it is located proximally to
the adventitia of the coronary arteries, it could play signifi-
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B Ba ac ck kg gr ro ou un nd d: : Epicardial fat is a visceral thoracic fat and known to be related with presence of dyslipidemia and coronary
arterial stenosis. We evaluated the effects and differences of statins on epicardial fat thickness (EFT) in patients underwent
successful percutaneous coronary intervention (PCI).
M Me et th ho od ds s: : In this retrospective cohort study, we enrolled consecutive patients underwent successful PCI and scheduled six to
eight-months follow-up coronary angiography from March 2007 to June 2009. EFT was measured by echocardiography twice
at the time of PCI and the follow-up coronary angiography. We included 145 patients (58 females; mean, 63.5 ±9.5 years). 
R Re es su ul lt ts s: : Of the 145 patients, 82 received 20 mg of atorvastatin (atorvastatin group) and 63 medicated with 10 mg of
simvastatin with 10 mg of ezetimibe (simvastatin/ezetimibe group). With statin treatments, total cholesterol concentration
(189.1 ± 36.1 to 143.3 ± 36.5 mg/dL, p < 0.001), triglycerides (143.5 ± 65.5 to 124.9 ± 63.1 mg/dL, p = 0.005), low density
lipoprotein-cholesterol (117.4 ± 32.5 to 76.8 ± 30.9 mg/dL, p < 0.001) and EFT (4.08 ± 1.37 to 3.76 ± 1.29 mm, p < 0.001)
were significantly decreased. Atorvastatin and simvastatin/ezetimibe showed similar improvements in the cholesterol profiles.
However, atorvastatin decreased EFT more significantly than simvastatin/ezetimibe (EFT change 0.47 ± 0.65 in the
atorvastatin vs. 0.12 ±0.52 mm in the simvastatin/ezetimibe group; p = 0.001).
C Co on nc cl lu us si io on n: : In this study, the atorvastatin group showed significant reduction in EFT than in the simvastatin/ezetimibe
group. This might be originated from the statin difference. More large, randomized study will be needed to evaluate this statin
difference.
KEY WORDS: Percutaneous coronary intervention∙Epicardial fat∙Statins.
online © ML Commcant roles in the pathogenesis of coronary artery disease
(CAD).
1-4) With technical improvement, epicardial fat can
be measured with the transthoracic echocardiography (TTE)
and it is correlated well with abdominal adipose tissue by the
magnetic resonance imaging.
5) Because TTE can be used
repeatedly without giving additional harm to the patients, it
may be the best method to compare the effects of treatment. 
Recently, the use of statins has been associated with decreas-
ed adipokine release from visceral adipose tissue.
6) We hypo-
thesized that the use of statins can be associated with a
decrease in epicardial fat thickness (EFT). By using TTE, we
evaluated the effects of statins on the epicardial fat tissue in
patients with coronary artery disease underwent percutaneous
coronary intervention (PCI) and compared the effects of
statins. 
M Me et th ho od ds s
This study is a retrospective cohort study. We included
patients with chronic stable angina who were scheduled to
undergo PCI. All patients were included in the prospective
study in our institution. EFT was measured consecutively in
the patients underwent successful PCI and scheduled to be
taken the follow up coronary angiography after six to eight
months from March 2007 to June 2009. The EFT was cal-
culated twice on the time of PCI and the follow up angio-
graphy. All patients were medicated with any type of statins
without any limitations and targeted to lower the low density
lipoprotein (LDL)-cholesterol less than 70 mg/dL. Patients
who were treated with one of two statins [atorvastain (20
mg) or simvas-tatin/ezetimibe (10/10 mg)] were included in
this study. 
The exclusion criteria in this study were the same as the
exclusion criteria of the prospective studies. Also, patients
without follow-up echocardiographic examinations and
patients with inadequate echocardiographic images in which
EFT could not be measured were also excluded.
Plasma lipid profiles, high sensitive C-reactive protein (hs-
CRP), blood urea nitrogen level and serum creatinine were
measured. Clinical profiles were acquired from the medical
records. This study protocol was approved by our institutional
review board, and all patients gave their written informed
consent for use of their medical records.
Measurement of echocardiographic epicardial 
fat thickness 
Two-dimensional transthoracic echocardiography (GE
Vivid 7 with 4.0 MHz transducer; GE medical systems, An-
dover, MA, USA) was used to calculate EFT. We recorded
three cycles of the two-dimensional parasternal long-axis
view and the parasternal short-axis view at the basal left ven-
tricular level. After increasing the depth of each view until the
aortic and mitral valves were positioned lowest on the screen
to allow for better visualization and accurate estimation of
EFT. EFT was calculated on the free wall of the right ventri-
cle (RV) in the still images obtained at end diastole on both
parasternal long-axis and short-axis views. The anterior echo-
lucent space between the RV outer wall and the linear echo-
dense parietal pericardium was considered to be epicardial fat
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Fig. 1. Echocardiographic measurement of EFT with parasternal long-axis view. Anterior echo-lucent space between the linear echo-dense parietal
pericardium and the epicardium was considered to be epicardial adipose tissue (arrows). Mediastinal fat, seen as an echo-lucent area located above
the parietal pericardium, was not included in the measurement. EFT was decreased from 6.0 mm at the time of percutaneous coronary intervention (A)
to 5.2 mm at the time of follow-up angiography after 6 months (B). PCI: percutaneous coronary intervention, EFT: epicardial fat thickness.
AB At the PCI At the follow up(Fig. 1). We excluded mediastinal fat, presenting as an echo-
lucent area above the parietal pericardium, in the measure-
ment of EFT. The mean value of two images obtained in the
parasternal long-axis and short-axis views was calculated. To
compare its change more objectively, we used standard images
of the heart and tried to find as similar images of the previous
study. 
Statistical analysis
We used a commercial program, SPSS version 12.0 (SPSS
Inc., Chicago, Illinois, USA), for statistical analysis. All con-
tinuous variables are expressed as mean ± SD and categorical
variables are expressed as number and percentage. Intra- and
inter-observer agreements in the EFT were tested using base-
line echocardiography of 12 patients according to the statis-
tical methods proposed by Bland and Altman.
7) 
Inter-and intra-observer agreements-All measurements
were transformed to an equivalent percentage scale of agree-
ment, according to the following formula;
Agreement index = 100 -
| X1st -X2nd |
(X1st + X2nd)/2   
in which X1st and X2nd are measures obtained in twice-
repeated evaluation using same technique in the same pati-
ent. The measure of reproducibility was 2 SD of the intrao-
bserver and interobserver agreement indexes. Therefore,
these coefficient of variations (COV) were equal to 2 SD of 
. The intraobserver agreement was 93.8% and the
COV was 3.2% (p < 0.001). The interobserver agreement
was 93.2% and the COV was 4.6% (p < 0.001).
We compared the clinical characteristics of patients who
were medicated with atorvastatin and simvastatin with ezeti-
mibe. Between two groups, comparisons of continuous
variables were performed using the independent sample t-
test and categorical variables by using χ 2 test. The effects of
statins were analyzed by using paired sample t-test. A p-value
less than 0.05 considered statistically significant. 
R Re es su ul lt ts s
During the study period, 181 patients were scheduled to
have the follow up coronary angiography as participants of
clinical trial after six to eight months later. They were medi-
cated with any type of cholesterol lowering agents. Eighty-
eight, 65, and 23 patients were medicated with 20 mg of
atorvastatin, 10 mg of simvastatin plus 10 mg of ezetimibe,
and other statins, respectively. The remaining 5 patients were
not treated with statins due to complications associated with
statin use.
After exclusion of 36 patients (23 patients were treated
with other statins, 8 patients without follow-up echocardio-
graphies with optimal images, and 5 patients not treated
with statins for any reason), we included 145 patients (58
females; mean, 63.5 ± 9.5 years). Of the 145 patients, 82
received 20 mg of atorvastatin (atorvastatin group) and 63
medicated with 10 mg of simvastatin with 10 mg of ezeti-
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| X1st -X2nd | 
(X1st + X2nd)/2
Table 1. Baseline characteristics according to the treatment modalities
Atorvastatin group (n = 82) Simvastatin/ezetimibe group (n = 63) p-value
Female gender 33 (40.2%) 25 (39.7%) 1.000
Age (years) 64.6 ± 9.4 62.0 ± 9.5 0.094
Body mass index (kg/m
2) 25.0 ± 3.2 25.1 ± 2.9 0.854
Cardiovascular risk factors
Hypertension 37 (45.1%) 29 (46.0%) 1.000
Diabetes 21 (25.6%) 17 (27.0%) 0.852
Dyslipidemia 33 (40.2%) 28 (55.6%) 0.616
Current smoker 13 (15.9%) 8 (12.9%) 0.881
Laboratory findings
Blood urea nitrogen (mg/dL) 17.2 ± 9.5 17.8 ± 21.2 0.825
Creatinine (mg/dL) 1.1 ± 0.8 1.1 ± 1.2 0.839
hs-CRP (mg/L) 3.2 ± 2.9 4.5 ± 6.8 0.215
Total cholesterol (mg/dL) 185.8 ± 31.6 193.3 ± 40.8 0.226
Triglyceride (mg/dL) 136.4 ± 63.4 152.1 ± 69.6 0.161
LDL-cholesterol (mg/dL) 116.6 ± 28.6 118.5 ± 39.6 0.743
HDL-cholesterol (mg/dL) 42.0 ± 9.5 42.7 ± 9.8 0.636
Epicardial fat thickness (mm) 4.17 ± 1.38 3.96 ± 1.37 0.542
Pattern of coronary artery disease 0.348
One vessel disease 22 (26.8%) 24 (38.1%)
Two vessel disease 24 (29.3%) 15 (23.8%)
Three vessel disease 36 (43.9%) 24 (38.1%)
hs-CRP: high sensitive C-reactive protein, LDL-cholesterol: low density lipoprotein-cholesterol, HDL-cholesterol: high density lipoprotein-cholesterolmibe (simvastatin/ezetimibe group). Their baseline clinical
characteristics were listed on the Table 1. There were tenden-
cies of higher concentration of total cholesterol, triglycerides
and hs-CRP in the simvastatin/ezetimibe group. However,
there was no significant statistical difference. The pattern of
coronary artery disease was similar in the two groups. 
With statin treatments, total cholesterol concentration
(189.1 ± 36.1 to 143.3 ± 36.5 mg/dL, p < 0.001), trigly-
cerides (143.5 ± 65.5 to 124.9 ± 63.1 mg/dL, p = 0.005),
LDL-cholesterol (117.4 ± 33.0 to 74.7 ± 30.6 mg/dL, p <
0.001), hs-CRP (3.8 ± 5.3 to 2.5 ± 2.9 mg/L, p = 0.034) and
EFT (4.08 ±1.37 to 3.76 ±1.29 mm, p< 0.001) were signi-
ficantly decreased. However, high density lipoprotein (HDL)-
cholesterol (42.0 ± 9.5 to 42.3 ± 9.5 mm, p = 0.723) and
body mass index (BMI)(25.1 ± 3.1 to 24.9 ± 3.3 kg/m
2, p =
0.272) were not changed. 
Atorvastatin and simvastatin/ezetimibe showed similar
improvements in the cholesterol profiles. Their effects of sta-
tins were listed on Table 2. In the atorvastatin group, there
was significant reduction of triglyceride concentration (136.4
± 63.4 to 116.4 ± 58.4 mg/dL, p = 0.002). However, there
was insignificant reduction of triglyceride concentration in
the simvastatin/ezetimibe group (152.1 ± 69.6 to 135.6 ±
67.6 mg/dL, p = 0.387). Moreover, atorvastatin was associat-
ed with decreased EFT more significantly than simvasta-
tin/ezetimibe (EFT change; 0.47 ± 0.65 in the atorvastatin
vs. 0.12 ± 0.52 mm in the simvastatin/ezetimibe group; p =
0.001)(Fig. 2). The type of statin was the only independent
factor associated with the EFT change as a result of multi-
variate analysis (Table 3).
D Di is sc cu us ss si io on n
In this study, we demonstrated the effects of statins on
epicardial fat in patients with CAD underwent PCI. Despite
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Table 2. Cholesterol profiles and epicardial fat thickness at the baseline and the follow-up
Atorvastatin group (n = 82) Simvastatin/ezetimibe group (n = 63)
p-value
Baseline Follow-up p-value Baseline Follow-up p-value
hs-CRP (mg/L) 3.2 ± 2.9 2.3 ± 3.0 0.112 4.5 ± 6.8 2.7 ± 2.8 0.132 0.226
Total cholesterol (mg/dL) 185.8 ± 31.6 141.1 ± 35.30 < 0.001 193.3 ± 40.8 146.3 ± 38.10 < 0.001 0.674
Triglyceride (mg/dL) 136.4 ± 63.4 116.4 ± 58.40 0.002 152.1 ± 69.6 135.6 ± 67.60 0.288 0.387
HDL-cholesterol (mg/dL) 42.0 ± 9.5 41.6 ± 10.0 0.613 42.7 ± 9.8 43.1 ± 9.60 0.213 0.226
LDL-cholesterol (mg/dL) 116.6 ± 28.6 75.9 ± 27.1 < 0.001 118.5 ± 39.6 73.3 ± 34.7 < 0.001 0.248
EFT (mm) 4.17 ± 1.38 3.71 ± 1.21 < 0.001 3.96 ± 1.37 3.84 ± 1.40 0.062 0.001
hs-CRP: high sensitive C-reactive protein, LDL-cholesterol: low density lipoprotein-cholesterol, HDL-cholesterol: high density lipoprotein-cholesterol, EFT: 
epicardial fat thickness
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Fig. 2. Change of epicardial fat thickness (EFT) according to the statin (A: atorvastatin, B: simvastatin/ezetimibe). Atorvastatin was associated with
significant reduction of EFT.
ABatorvastatin and simvastatin/ezetimibe equally lowered the
cholesterol profiles in them, atorvastatin significantly dec-
reased the EFT more than that of simvastatin/ezetimibe. 
The epicardium, a visceral layer of the pericardium, is
composed with mesothelial cells.
8) Epicardial fat, accumulated
adipose tissue covers 80% of the heart’s surface, is present
along the course of the coronary arteries, over the RV, anterior
surface and at the apex. It is closely contacted to the myocar-
dium and supplied by branches of the coronary arteries.
9)
Mature adipocytes are located in the epicardial fat especially
anterior to the right ventricle (RV) and these may act as more
readily available, direct sources of free fatty acid for cardiomyo-
cytes.
10)11) The reported mean value of the EFT in patients
with CAD is about 4.0 mm,
4) which is similar to our result.  
Recently, the scientific and clinical interest in epicardial fat
is rapidly growing.
12-14) Iacobellis and Sharma
14) showed that
echocardiographic assessment of epicardial fat can serve as a
new index of cardiac and visceral adiposity. Moreover, the
epicardial fat has known to be clinically correlated with
abdominal visceral adiposity measured by magnetic reso-
nance imaging,
15) presence of atherosclerosis,
16)17) and coronary
artery disease.
4)18)
Though it is unknown how much visceral fat loss is needed
to reduce cardiometabolic risk presently, the reduction of
visceral adipose tissue is known to be associated with a signi-
ficant improvement of the metabolic profile.
19) Busetto et al.
20)
reported that visceral adipose tissue loss in the phase of rapid
weight loss after laparoscopic adjustable silicone gastric
banding. 
Recently, the epicardial adipose tissue can be regarded as a
therapeutic target during clinical interventions modulating
the adipose tissue.
21) Iacobellis et al.
22) reported that signifi-
cant reduction of epicardial fat after weight loss during six-
month duration with very low calorie diet program in severely
obese patients. Moreover, the reduction of epicardial adipose
tissue was higher than changes of waist circumference and
BMI. The reduction of visceral adiposity was related with
the improvement of cardiac diastolic function.
22) We demon-
strated similar result of epicardial fat reduction by using
statins within relatively short duration in patients with
significant CAD underwent PCI. Though mean EFT was
decreased 7.0% during the study period, the EFT was signi-
ficantly decreased in the atorvastatin group than in the sim-
vastatin/ezetimibe group (10.0 ± 15.0% in the atorvastatin
group vs. 3.1 ± 13.3% in the simvastatin/ezetimibe group, p
= 0.001). Statins inhibits HMG CoA reductase (rate-limiting
step in cholesterol biosynthesis) in the liver, increases LDL-
receptor expression and activity, and enhances removal of
lipoprotein by LDL-receptor. It also reduces hepatic release
of lipoprotein into the blood circulation.
23) Despite of lipid
lowering effects, statins have other pleiotrophic effects includ-
ing inhibition of migration and proliferation of arterial myo-
cytes, inhibition of macrophage growth, inhibition of metal-
loproteinase secretion, and Inhibition of cell adhesion.
24)
Currently, there are no studies which have demonstrated the
statin effect (decrease) on the thickness of adipose tissues.
However, metabolic syndrome is associated with increased
visceral adiposity and increased production of pathologic
adiopokines,
25) and the use of atorvastatin and fenofibric
acids is associated with decreased adipokine release from
visceral adipose tissue.
6) The use of statin might decrease the
production of pathologic adipokines in the epicardial adi-
pose tissue, and the reduced adiopokine production might
subsequently be associated with a decrease in EFT.
There are many kinds of commercially available statins.
Though statins share similar properties, there are several
differences. Atorvastatin decreased the progression of carotid
intima-media thickness in the familial hypercholesterolemia
patients.
26) However, simvastatin/ezetimibe combination the-
rapy did not result in a significant difference in changes of
carotid intima-media thickness.
27) This different effects of
statins on the EFT might be due to statin difference. In this
study, the degree of cholesterol reduction and hs-CRP change
were similar in the two groups. However, the exact mechanism
of the EFT lowering was unknown. This might be originated
from cholesterol independent mechanisms of statins.
Albeit this study provides original and intriguing findings,
it may have also some limitations. First, this is a retrospective
Effects Statins on Epicardial Fat Thickness | | Jae-Hyeong Park, et al.
125
Table 3. Multivariate analysis for factors associated with a change in epicardial fat thickness
Variables Odd ratio 95% confidence interval p-value
Age (year) 0.011 -0.008 - 0.031 0.243
Gender (male = 1, female = 2) -0.033 -0.361 - 0.296 0.843
Change in total cholesterol -0.004 -0.024 - 0.015 0.660
Change in LDL-cholesterol 0.008 -0.014 - 0.030 0.481
Change in triglyceride 0.001 -0.004 - 0.005 0.854
Change in hs-CRP -0.004 -0.047 - 0.039 0.844
Pattern of CAD (1VD = 1, 2VD = 2, 3VD = 3) -0.022 -0.220 - 0.177 0.830
Type of statin (atorvastatin = 1, simvastatin/ezetimibe = 2) 0.509 0.162 - 0.855 0.005
hs-CRP: high sensitive C-reactive protein, CAD: coronary artery disease, 1VD: one vessel disease, 2VD: two vessel disease, 3VD: triple vessel diseasecohort study. The use of statin was not assigned randomly.
Moreover, the patients without follow up echocardiography
and inadequate echocardiographic image quality were ex-
cluded in this study. To evaluate this difference of the statins
on the EFT, more large randomized trial will be needed.
Second, the sample size in this study was relatively small.
Though there is statistically significant difference in the
lowering EFT, we believe further studies in a larger popula-
tion are necessary to confirm these data. Third, the echocar-
diography might not be the optimal technique for quanti-
fication of epicardial fat. Because echocardiography measures
EFT linearly, echocardiographic EFT may not reflect the
total epicardial fat volume exactly. However, echocardiogra-
phic examination is relatively accurate, easier and reliable
method. Moreover, it is more accessible than the magnetic
resonance imaging or computerized tomographic scanning,
and can be performed without giving any hazards including
radiation exposure or toxicity of radiocontrast agents. 
In conclusion, we demonstrated that statin, especially ator-
vastatin, use can be associated with significant reduction in the
EFT, a marker of visceral adiposity, in patients with signifi-
cant coronary artery disease. 
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